Can a newer drug protect heart health after kidney transplant?
NCT ID NCT06291077
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at kidney transplant patients who take immunosuppressants to prevent organ rejection. It compares the effects of belatacept, a newer drug, against standard anticalcineurins on blood vessel function. The goal is to see if belatacept improves vascular health and reduces heart risks. About 44 participants will be followed for 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belatacept
What this could lead to
If successful, this could show that switching to belatacept improves blood vessel function, potentially reducing heart risks in kidney transplant patients.
What could go wrong
This is a small, early-phase study with only 44 participants, so results may not apply broadly. Belatacept may not improve vessel function as hoped, and patients still need lifelong immunosuppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de ROUEN
RECRUITINGRouen, 76031, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact